EIA
ABBV icon

Eldridge Investment Advisors’s AbbVie ABBV Stock Holding History

Eldridge Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.08M Buy
9,563
+3
+0% +$665 0.46% 44
2025
Q4 		$2.18M Sell
9,560
-201
-2% -$45.8K 0.48% 38
2025
Q3 		$2.26M Buy
9,761
+4
+0% +$815 0.51% 37
2025
Q2 		$1.81M Buy
9,757
+524
+6% +$97.4K 0.38% 53
2025
Q1 		$1.93M Buy
9,233
+5
+0.1% +$972 0.45% 51
2024
Q4 		$1.64M Sell
9,228
-409
-4% -$75.2K 0.38% 58
2024
Q3 		$1.9M Buy
9,637
+4
+0% +$747 0.45% 52
2024
Q2 		$1.65M Buy
9,633
+609
+7% +$101K 0.42% 56
2024
Q1 		$1.64M Buy
9,024
+33
+0.4% +$5.69K 0.42% 57
2023
Q4 		$1.39M Sell
8,991
-95
-1% -$13.8K 0.36% 62
2023
Q3 		$1.35M Buy
9,086
+4
+0% +$587 0.45% 45
2023
Q2 		$1.22M Sell
9,082
-85
-0.9% -$12.5K 0.4% 50
2023
Q1 		$1.46M Buy
9,167
+5
+0.1% +$764 0.51% 44
2022
Q4 		$1.48M Sell
9,162
-8
-0.1% -$1.23K 0.52% 43
2022
Q3 		$1.23M Buy
9,170
+445
+5% +$63.9K 0.48% 42
2022
Q2 		$1.34M Buy
8,725
+4
+0% +$611 0.5% 38
2022
Q1 		$1.41M Sell
8,721
-39
-0.4% -$5.67K 0.48% 38
2021
Q4 		$1.19M Buy
8,760
+5
+0.1% +$591 0.39% 41
2021
Q3 		$944K Buy
8,755
+5
+0.1% +$571 0.34% 48
2021
Q2 		$986K Buy
8,750
+4
+0% +$450 0.36% 48
2021
Q1 		$946K Buy
8,746
+5
+0.1% +$535 0.37% 45
2020
Q4 		$937K Buy
8,741
+5
+0.1% +$480 0.39% 41
2020
Q3 		$765K Buy
8,736
+3
+0% +$282 0.36% 41
2020
Q2 		$857K Buy
8,733
+8
+0.1% +$704 0.43% 32
2020
Q1 		$665K Buy
8,725
+5
+0.1% +$426 0.38% 37
2019
Q4 		$772K Buy
8,720
+4
+0% +$332 0.38% 44
2019
Q3 		$660K Buy
8,716
+7
+0.1% +$480 0.34% 44
2019
Q2 		$633K Buy
8,709
+48
+0.6% +$3.77K 0.34% 42
2019
Q1 		$698K Buy
8,661
+5
+0.1% +$409 0.38% 41
2018
Q4 		$798K Buy
+8,656
New +$761K 0.49% 32

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eldridge Investment Advisors's ABBV Position: Q1 2026 in Review

Eldridge Investment Advisors increased its AbbVie (ABBV) stake by 0.03% in Q1 2026, buying an estimated $665 and bringing the position to 9,563 shares worth $2.08M. The position accounts for 0.46% of the portfolio, ranked #44.

Eldridge Investment Advisors first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.26M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Eldridge Investment Advisors held 9,563 shares of AbbVie worth $2.08M as of Q1 2026.
  • Eldridge Investment Advisors bought 3 AbbVie shares in Q1 2026, an estimated $665.
  • AbbVie made up 0.46% of Eldridge Investment Advisors's portfolio in Q1 2026, its #44 holding.
  • Eldridge Investment Advisors first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Eldridge Investment Advisors's AbbVie position peaked at $2.26M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Eldridge Investment Advisors's 13F filing for Q1 2026, filed 11 May 2026.